Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Chemoradiotherapy no better than chemo alone in endometrial carcinoma

Publish date:: June 19, 2019

Key clinical point: Chemoradiotherapy was not associated with improved relapse-free survival versus chemotherapy alone in patients with locally advanced endometrial cancer.

Major finding: At 60 months, the proportion of patients alive and relapse free was 59% and 58% in the chemoradiotherapy and chemotherapy alone arms, respectively (hazard ratio, 0.90; 90% confidence interval, 0.74-1.10).

Study details: A phase 3 trial of 736 patients with stage III or IVA endometrial carcinoma.

Disclosures: The National Cancer Institute supported the study. The authors reported financial affiliations with AstraZeneca, Clovis, Genentech, the GOG Foundation, Tesaro, and several others.

Citation:

Matei D et al. N Engl J Med. 2019 Jun 13. doi: 10.1056/NEJMoa1813181.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gynecologic Cancer

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

Is diagnostic hysteroscopy safe in patients with type 2 endometrial cancer?,

Cervical cancer recurrence patterns differ after laparoscopic and open hysterectomy,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Half of women treated for gynecologic cancers miss or skip doses of oral drugs,